Home › NCT06512259

AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

A Retrospective Study To Evaluate The Safety And Effectiveness Of AlloMend® Acellular Dermal Matrix Used In Post Mastectomy Pre-Pectoral Breast Reconstruction And Followed For Up To 6-Months Post-Operatively.

Who can join

Ages 18 and older · Women

Inclusion Criteria:

Patients must meet the following inclusion criteria to participate in this study:

* Diagnosed by a physician and required a single or double mastectomy followed by Pre-Pectoral Breast Reconstruction surgery with the use of AlloMend® Acellular Dermal Matrix allograft;
* Surgical intervention using AlloMend® Acellular Dermal Matrix allograft was used;
* Has completed or will complete the anticipated clinically indicated follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months post-surgical intervention.

Exclusion Criteria:

Patients must not meet any of the following criteria to be considered for this clinical trial:

* Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
* Did not have post-operative evaluations at the clinical site.

About the study

This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

What is being tested

• AlloMend® Acellular Dermal Matrix allograft (other)

Sponsor: AlloSource · Participants: 200 · Started: Oct 19, 2023

Contact the study team

• Elizabeth Esterl, DNP, MS, RN · Phone: 7207326231
• Paige McHenry, MS, ATC, CCRA · Phone: 2154997062

Official record on ClinicalTrials.gov — NCT06512259

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.